Last updated: March 14, 2024
Sponsor: Emergent BioSolutions
Overall Status: Terminated
Phase
3
Condition
Healthy Volunteers
Hepatitis B
Hepatitis
Treatment
hepatitis B vaccine
Clinical Study ID
NCT01311674
HB-012
Ages 20-55 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
- Age 20-55 years.
- Naïve or previously hepatitis B-vaccinated males or females.
- Normal and healthy as determined by medical history, physical exam, vital signs andclinical laboratory tests
- Subject must meet all required/recommended subject suitability criteria that pertainto normal source plasma donors with the following exception:
- Subjects who previously tested positive for HBsAg may be accepted into the anti- HBsprogram provided they now test negative and meet all other normal donor suitabilitycriteria.
- Written informed consent.
Exclusion
Exclusion Criteria:
- Subjects who have received a hepatitis B vaccination in the previous six months.
- History of hypersensitivity to yeast or any components of the Engerix-B® vaccine
- History of hypersensitivity to any hepatitis B-containing vaccine.
- Use of any investigational product within the past 30 days or during the course of thestudy.
- Use of steroids or immunosuppressives during the study period.
- Received immunosuppressive therapy (including systemic steroids) within 30 days beforestudy entry
- Subjects who have received cytotoxic therapy (in the previous 5 years prior to studyentry)
- Received parenteral immune globulin products or blood products within 3 months beforestudy entry with the following exceptions:
- RhoGAM (or equivalent anti-D immune globulin) within 6 weeks before study entry;
- Pertussis immune globulin: no exclusion
- Received parenteral immune globulin products or blood products (within 3 months beforestudy entry)
- Past, present, or suspected IV drug use
- Positive HIV, HBV* or HCV test result (*except as described above in InclusionCriteria)
- Autoimmune disease (such as, but not limited to demyelinating disease)
- Subjects with cancer, heart disease (including hospitalization for myocardialinfarction, arrhythmia, syncope, congestive heart failure), uncontrolled hypertension,uncontrolled insulin-dependent diabetes mellitus, seizures, kidney disease
- Severely or morbidly obese, or higher obesity classification, which corresponds to BMIof 35 or higher
- Pregnancy or lactation.
Study Design
Total Participants: 141
Treatment Group(s): 1
Primary Treatment: hepatitis B vaccine
Phase: 3
Study Start date:
September 01, 2009
Estimated Completion Date:
March 11, 2011
Study Description
Connect with a study center
Cangene Plasma Resources, Mid-Florida
Altamonte Springs, Florida 32701
United StatesSite Not Available
Cangene Plasma Resources, Frederick
Frederick, Maryland 21702
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.